Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation

Experimental and Clinical Cardiology

Volumn 14, Issue 1, 2009, Pages

  Anis, Rafik R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Atrial fibrillation

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IBUTILIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FIBROSIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; RECURRENT DISEASE; REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

EID: 70349285277     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Garg R, S Yusuf. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.
2. Kober L, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New Eng J Med 1995;333:1670-6.
3. Pizzetti F, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart 2001;86:527-32.
4. Healey JS, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A Meta-Analysis. J Am Coll Cardiol 2005:45;1832-9.
5. Anne W, et al. Atrial fibrillation after radiofrequency ablation of atrial flutter: Preventive effect of angiotensin converting enzyme inhibitors, angiotensin-II receptor blockers, and diuretics. Heart 2004;9:1025-30.
6. Goette A, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cadiol 2000;6:1669-77.
7. Rik Willems, et al. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. J Cardiovasc Electrophysiol 2001;12:1387-92.
8. Li D, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;21:2608-14.
9. Vermes E, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003;23:2926-31.
10. Madrid AH. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circualtion 2002;106:331-336.
11. Shi Y, et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001:52;217-25.
12. Nakashima H, et al. Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation 2000:101;2612-7.
13. Ruiz-Ortega M, et al. Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension 2001;38:1382-7.
14. Willems R, et al, Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. J Cardiovasc Electrophysiol 2001;12:1387-92.
15. Nattel, S. Atrial electrophysiological remodelling caused by rapid atrial activation underlyiong mechanisms and clinical relevance to atrial fibrillation. Cardiovasc Res 1999;42;298-308.
16. Tang L, Both K, Taylor R. ACE inhibition and fibroblast growth factor in cultured human vascular smooth muscle. Vasc Med 1999;4:129-34.
17. McEwan PE, et al. Differential Effects of Angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998;98:2765-73.
18. Dostal DE. Regulation of cardiac collagen: Angiotensin and cross-talk with local growth factors. Hypertension 2001;37:841-4.
19. Verheule S, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-{beta}1. Circ Res 2004;94:1458-65.
20. Hanna N, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004;63:236-44.
21. Xiao HD, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004;165:1019-32.
22. Engelmann MDM, JH Svendsen. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92.
23. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
24. Ommen SR, JA Odell, Stanton MS. Atrial Arrhythmias after Cardiothoracic Surgery. N Engl J Med 1997;336:1429-34.
25. Bruins P, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997:96;3542-8.
26. Issac TT, H. Dokainish NM, Lakkis. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J Am Coll Cardiol 2007:50;2021-8.
27. Korantzopoulos P, et al. A trial fibrillation and electrical remodeling: The potential role of inflammation and oxidative stress. Med Sci Monit 2003;9:9.
28. Aviles RJ, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;24:3006-10.
29. Chung MK, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91.
30. Psychari SN, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005;95:764-7.
31. Watanabe T, et al. C-Reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 2005;20:45-9.
32. Webster MWI, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985;6:566-9.
33. Ravelli F and M. Allessie, Effects of Atrial Dilatation on Refractory Period and Vulnerability to Atrial Fibrillation in the Isolated Langendorff-Perfused Rabbit Heart. Circulation 1997;96:1686-95.
34. Cha TJ, et al. Dissociation Between Ionic Remodeling and Ability to Sustain Atrial Fibrillation During Recovery From Experimental Congestive Heart Failure. Circulation 2004;109:412-8.
35. Alsheikh-Ali AA, et al. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 2004;147:1061-5.
36. Madrid AH, et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-Analysis of Randomized Controlled Clinical Trials. PACE - Pacing and Clinical Electrophysiology 2004:27:1405-10.
37. Li D, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing - Induced congestive heart failure. Circulation 2001:104;2608-14.
38. Shi Y, et al. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002:54;456-61.
39. Hansson L, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet 1999:354;1751-6.
40. Wachtell K, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End point reduction in hypertension (LIFE) study. J Am Coll Cardiol, 2005:45;712-9.
41. Julius S, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004:363;2022-31.
42. Anand K, et al. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006:152;217-22.
43. Healey JS, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005:45;1832-9.
44. Hansson L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999:353;611-6.
45. Anique D, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006:152;86-92.
46. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345;1667-75.
47. Pedersen OD, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999:100;376-80.
48. Olsson LG, et al. Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol 2006:47;1997-2004.
49. Van Den Berg MP, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995:1;355-63.
50. Fogari RMM, Amedeo MD, Destro Maurizio MD, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006 47;46-50.
51. Ueng KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J 2003:24;2090-8.
52. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 2006:46;21-8.
53. Madrid AH, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A Prospective and Randomized Study. Circulation 2002:106;331-6.
54. Oral H, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. 1999:1849-54.
55. Zaman AG, et al. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004:147;823-7.
56. Richter B, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: No effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007:153;113-9.
57. Holubarsch C, et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium: An in vitro study under physiological experimental conditions. Circulation 1993:88;1228-37.
58. Holubarsch C, et al. Functional significance of angiotensin receptors in human myocardium. Significant differences between atrial and ventricular myocardium. Eur Heart J 1994:5(SUPPL D); 88-91.
59. Vaziri SM, et al. Echocardiographic predictors of nonrheumatic atrial fibrillation: The Framingham Heart Study. Circulation 1994. 89;724-30.
60. Kalifa J, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003:108;668-71.
61. Li D, et al. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999:100; 87-95.
62. Wijffels MC, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995:92;1954-68.
63. Salehian O, et al. Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007:154;448-53.
64. Murray KT, et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004:1;669-75.
65. Teo KK, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004:148;52-61.